Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours 2

1025 - RADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract

Date

20 Dec 2015

Session

Gastrointestinal tumours 2

Presenters

James Yao

Citation

Annals of Oncology (2015) 26 (suppl_9): 40-41. 10.1093/annonc/mdv522

Authors

J.C. Yao1, S. Singh2, E. Wolin3, M. Voi4, L.B. Pacaud5, J. Lincy5, C. Sachs5, J.W. Valle6, E. van Cutsem7, Y. Shimada8, D. Oh9

Author affiliations

  • 1 Department Of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 2 Department Of Medicine, Sunnybrook Health Sciences Centre, Toronto/CA
  • 3 Department Of Neuroendocrine And Gastrointestinal Oncology, Markey Cancer Center - University of Kentucky, Lexington/US
  • 4 Oncology Business Unit, Novartis Pharmaceuticals Corporation, East Hanover/US
  • 5 Oncology Business Unit, Novartis Pharma AG, Basel/CH
  • 6 Department Of Medical Oncology, University of Manchester, Institute of Cancer Studies, The Christie Hospital, M20 4BX - Manchester/GB
  • 7 Department Of Digestive Oncology, University Hospitals Gasthuisberg/Leuven and KULeuven, La Louviere/BE
  • 8 Department Of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo/JP
  • 9 Department Of Internal Medicine, Seoul National University Hospital, Seoul/KR
More

Abstract 1025

Aim/Background

Effective therapeutic options for advanced, nonfunctional NET of lung/GI origin are limited. RADIANT-4 evaluated the efficacy and safety of EVE in this NET population.

Methods

Patients (pts) with advanced, progressive, well-differentiated, nonfunctional lung/GI NET were randomized (2:1) to EVE (10 mg/d) or placebo (PBO), both with best supportive care. Pts were stratified by tumor origin, WHO performance status (PS), and prior SSA use. Primary endpoint was PFS (central review, modified RECIST 1.0). Secondary endpoints included OS, objective response rate (ORR), disease control rate (DCR), and safety.

Results

302 pts were randomized to EVE (205) or PBO (97); median age, 63 y; 53% females; G1/G2: 64%/35%; WHO PS: 0, 74% or 1, 26%; majority (76%) were Caucasian; most common primary tumor sites: lung (30%), ileum (24%). Both arms were similar with respect to prior SSA use (53% in EVE vs 56% in PBO), chemotherapy (26% vs 24%), radiotherapy including PRRT (22% vs 20%) and locoregional therapies (11% vs 10%). Median PFS by central review was 11.0 mo (95% CI, 9.2–13.3) in EVE and 3.9 mo (95% CI, 3.6–7.4) in PBO arm (HR, 0.48; 95% CI, 0.35–0.67; P < 0.001). Investigator-assessed PFS was consistent with central review. Subgroup analyses of PFS by stratification factors were consistent with primary efficacy analysis. ORR (all partial responses) was 2% (4 pts) in EVE vs 1% (1) in PBO. DCR was higher in EVE vs PBO (82% vs 65%). 9% in EVE vs 27% pts in PBO arm had progressive disease as best outcome. A pre-planned interim OS analysis favored everolimus arm (HR, 0.64; 95% CI, 0.40–1.05; P = 0.037; threshold P = 0.0002). AEs were mainly G1/2; most common G3/4 AEs (EVE vs PBO): diarrhea (9% vs 2%), stomatitis (7% vs 0), abdominal pain (5% in each), and anemia (5% vs 2%).

Conclusions

RADIANT-4, the first large, PBO-controlled, phase 3 study in pts with advanced, progressive, nonfunctional lung/GI NET, provided unequivocal evidence for the efficacy of EVE in this population. Everolimus showed statistically significant and clinically meaningful 7.1-month prolongation of PFS vs PBO. EVE was well tolerated and AEs were consistent with the known safety profile.

Clinical trial identification

NCT01524783

Disclosure

J.C. Yao: consulting or advisory role – Ipsen, Lexicon, Novartis; research funding to Institute – Novartis. S. Singh: honoraria – Novartis; consulting or advisory role – Novartis; research funding to Institute - Novartis; travel, accommodation, expenses – Novartis. E. Wolin: consulting or advisory role – Celgene, Ipsen, Novartis. M. Voi, L.B. Pacaud, J. Lincy, C. Sachs: employment – Novartis; Stock and other ownership interests – Novartis. J.W. Valle: honoraria – Novartis; consulting or advisory role – Novartis; Research Funding to Institute – Novartis. E. Van Cutsem: research funding to Institute – Novartis. Y. Shimada: research funding to Institute - Chugai Pharma, Lilly, Novartis, Taiho Pharmaceutical. D.-Y. Oh: no relationships to disclose.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings